ANDA 91034, held by Zambon. Dorzolamide Hydrochloride.
As of Nov 21, 2026, ANDA 91034 (Dorzolamide Hydrochloride), held by Zambon, was first approved by FDA on Dec 4, 2013, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 4, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dorzolamide HydrochlorideEQ 2% BASE · solution/drops;ophthalmic | Dorzolamide Hydrochloride | Discontinued |
| Apr 6, 2015 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 4, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters